Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;17(12):972-81.
doi: 10.1007/s12094-015-1434-4. Epub 2015 Dec 15.

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

E Aranda  1   2 , J Aparicio  3 , V Alonso  4   5 , X Garcia-Albeniz  6 , P Garcia-Alfonso  7 , R Salazar  8 , M Valladares  9 , R Vera  10 , J M Vieitez  4   11 , R Garcia-Carbonero  4   12
Affiliations

SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015

E Aranda et al. Clin Transl Oncol. 2015 Dec.

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer dead in Spain. About half the patients will eventually develop distant metastases. However, as treatment options are expanding, prognosis has steadily improved over the last decades. Management of advanced CRC should be discussed within an experienced multidisciplinary team to select the most appropriate systemic treatment (chemotherapy and targeted agents) and to integrate surgical or ablative procedures when indicated. Disease site and extent, resectability, tumor biology and gene mutations, clinical presentation, patient preferences, and comorbidities are key factors to design a customized treatment plan. The aim of these guidelines is to provide synthetic recommendations for managing advanced CRC patients.

Keywords: Chemotherapy; Colorectal cancer; Guidelines; Metastases; Surgery; Targeted agents.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Therapeutic strategies in advanced colorectal cancer. Patients appropriate for intensive therapy. Note Front line treatment should consider clinical symptoms, comorbid conditions, prior adjuvant therapy, tumor biology and dynamics, and potential ability for metastasis resection. BV bevacizumab, XELOX oxaliplatin + capecitabine, FOLFOX biweekly oxaliplatin + infusional 5FU/LV, FOLFIRI biweekly irinotecan + infusional 5FU/LV, wt wild type. *If available
Fig. 2
Fig. 2
Therapeutic strategies in advanced colorectal cancer. Patients appropriate for intensive therapy. Note Front line treatment should consider clinical symptoms, comorbid conditions, prior adjuvant therapy, tumor biology and dynamics, and potential ability for metastasis resection. BV bevacizumab, XELOX oxaliplatin + capecitabine, FOLFOX biweekly oxaliplatin + infusional 5FU/LV, FOLFIRI biweekly irinotecan + infusional 5FU/LV, wt wild type. *If available
Fig. 3
Fig. 3
Therapeutic strategies in advanced colorectal cancer in patients who cannot tolerate intensive therapy. BV bevacizumab, 5FU/LV 5-fluorouracil/leucovorin, CT chemotherapy. *RAS wild type only. +If available
See this image and copyright information in PMC

References

    1. GLOBOCAN 2012. International Agency for Research on Cancer (World Health Organization) [Internet]. [cited 2015 Jul 10]. http://globocan.iarc.fr.
    1. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–144. doi: 10.1086/321805. - DOI - PubMed
    1. Edge SBB, Compton CC, Fritz AG, Greene FL, Trotti A. American Join Committee on Cancer’s (AJCC) Cancer Staging Manual. 7. New York: Springer; 2010.
    1. Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151–1156. doi: 10.1093/jnci/djt173. - DOI - PMC - PubMed
    1. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, On Behalf of the ESMO Guidelines Working Group Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Decision making. Ann Oncol. 2014;25(suppl. 3):iii1–iii9. doi: 10.1093/annonc/mdu260. - DOI - PubMed